Quoin Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Quoin Pharmaceuticals Ltd
QNRX Stock  USD 6.70  0.12  1.76%   
Quoin Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Quoin Pharmaceuticals' valuation are provided below:
Market Capitalization
4 M
Earnings Share
(34.62)
We have found one hundred twenty available trending fundamental ratios for Quoin Pharmaceuticals, which can be analyzed and compared to other ratios and to its competitors. All investors should make sure to check out all of Quoin Pharmaceuticals recent market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road. Market Cap is likely to drop to about 82.8 K in 2025. Enterprise Value is likely to rise to about (3.4 M) in 2025
Check Quoin Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Quoin Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 118.9 K, Other Operating Expenses of 6.6 M or Research Development of 2.8 M, as well as many indicators such as Dividend Yield of 7.58, Ptb Ratio of 0.0 or Book Value Per Share of 65.27. Quoin financial statements analysis is a perfect complement when working with Quoin Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Quoin Stock
Check out the analysis of Quoin Pharmaceuticals Correlation against competitors.

Quoin Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets9.4 M15.7 M7 M
Slightly volatile
Total Current Liabilities3.6 M4.2 M2.5 M
Slightly volatile
Property Plant And Equipment Net2.3 M2.2 M998.4 K
Slightly volatile
Cash3.7 M3.6 M2.6 M
Slightly volatile
Non Current Assets Total779.6 K783.3 K588.6 K
Slightly volatile
Cash And Short Term Investments8.2 M14.1 M6.1 M
Slightly volatile
Net Receivables68.1 K69.6 K69.6 K
Slightly volatile
Common Stock Shares Outstanding164.5 K134 K104.2 K
Slightly volatile
Liabilities And Stockholders Equity9.4 M15.7 M7 M
Slightly volatile
Other Current Assets912.6 K869.1 K290.8 K
Slightly volatile
Other Stockholder Equity67.7 B64.4 B8.3 B
Slightly volatile
Total Liabilities5 M6.5 M3.4 M
Slightly volatile
Total Current Assets8.7 M14.9 M6.4 M
Slightly volatile
Short and Long Term Debt Total3.8 K4.1 K46.6 M
Pretty Stable
Non Current Liabilities Total2.2 M2.3 M440.7 M
Pretty Stable
Inventory0.80.90.9813
Slightly volatile
Short Term Debt655.5 K690 K46.7 M
Pretty Stable
Intangible Assets601.2 K483.3 K891.3 K
Slightly volatile
Short and Long Term Debt970.6 K1.1 M1.2 M
Slightly volatile
Other Liabilities298.9 K336.2 K366.6 K
Slightly volatile
Good Will386.3 M434.6 M473.8 M
Slightly volatile

Quoin Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization118.9 K100.5 K80.7 K
Slightly volatile
Other Operating Expenses6.6 M9.6 M6.4 M
Slightly volatile
Research Development2.8 M3.5 M2.9 M
Pretty Stable
Cost Of Revenue119.8 K119 K81.9 K
Slightly volatile
Total Operating Expenses6.6 M9.5 M6.4 M
Slightly volatile
Selling General Administrative6.2 B5.9 B764.8 M
Slightly volatile
Reconciled Depreciation98.4 K100 K51.4 K
Slightly volatile
Selling And Marketing Expenses4.8 B5.9 B6 B
Slightly volatile

Quoin Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow2.8 M2.4 M1.9 M
Slightly volatile
Depreciation105 M100 M12.9 M
Slightly volatile
Total Cash From Financing Activities7.2 M11 M5.1 M
Slightly volatile
End Period Cash Flow3.7 M3.6 M2.6 M
Slightly volatile
Other Cashflows From Financing Activities15.7 M11 M9.4 M
Slightly volatile
Change To Netincome973.5 K1 M1.4 M
Pretty Stable
Dividends Paid52.2 M58.7 M64 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Dividend Yield7.588.549.3054
Slightly volatile
Average Payables382.5 K509.5 K373.5 K
Slightly volatile
Capex To Depreciation2.612.163.5411
Slightly volatile
Payables Turnover0.170.180.4887
Very volatile
Cash Per Share99.681051.8 K
Slightly volatile
Days Payables Outstanding1.4 K1.7 K2 K
Pretty Stable
Income Quality8.0E-49.0E-40.6776
Slightly volatile
Intangibles To Total Assets0.02920.03080.1595
Pretty Stable
Current Ratio4.513.574.1706
Pretty Stable
Capex Per Share0.680.7151.4039
Slightly volatile
Average Receivables83.4 K44.4 K86.7 K
Slightly volatile
Interest Debt Per Share0.00330.00351.8 K
Pretty Stable
Debt To Assets2.0E-43.0E-45.0338
Pretty Stable
Graham Number25.2 K19.1 K24.7 K
Slightly volatile
Days Of Payables Outstanding1.4 K1.7 K2 K
Pretty Stable
Ebt Per Ebit983936121
Slightly volatile
Long Term Debt To Capitalization0.690.780.8466
Slightly volatile
Quick Ratio4.513.574.1706
Pretty Stable
Net Income Per E B T0.650.90.8249
Pretty Stable
Cash Ratio0.820.86661.628
Pretty Stable
Operating Cash Flow Sales Ratio14.7821.1318.4021
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.171.141.0638
Slightly volatile
Debt Ratio2.0E-43.0E-45.0338
Pretty Stable
Gross Profit Margin1.11.31.3607
Very volatile

Quoin Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap82.8 K87.2 K13.5 M
Slightly volatile

Quoin Fundamental Market Drivers

Cash And Short Term Investments14.1 M

Quoin Upcoming Events

13th of March 2024
Upcoming Quarterly Report
View
13th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
13th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Quoin Pharmaceuticals Financial Statements

Quoin Pharmaceuticals investors use historical fundamental indicators, such as Quoin Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Quoin Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue(540.00)(567.00)
Cost Of Revenue119 K119.8 K
Sales General And Administrative To Revenue(25.61)(26.89)
Research And Ddevelopement To Revenue(26.54)(27.86)
Capex To Revenue(0.59)(0.62)
Revenue Per Share(116.82)(122.66)
Ebit Per Revenue(49.23)(51.69)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
USOICredit Suisse X Links
ULTYTidal Trust II
CONYYieldMax N Option

Additional Tools for Quoin Stock Analysis

When running Quoin Pharmaceuticals' price analysis, check to measure Quoin Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Quoin Pharmaceuticals is operating at the current time. Most of Quoin Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Quoin Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Quoin Pharmaceuticals' price. Additionally, you may evaluate how the addition of Quoin Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY